Page last updated: 2024-10-24

integrin binding involved in cell-matrix adhesion

Definition

Target type: molecularfunction

Any integrin binding that occurs as part of the process of cell-matrix adhesion. [GOC:dos]

Integrin binding plays a crucial role in cell-matrix adhesion, facilitating the attachment of cells to the surrounding extracellular matrix (ECM). Integrins are transmembrane receptors that bridge the intracellular cytoskeleton with the ECM. This binding process involves a complex interplay of molecular events, including:

1. **Ligand Recognition:** Integrins bind to specific ECM proteins, such as fibronectin, collagen, and laminin, through their extracellular domains. This interaction is highly specific and involves complementary shapes and chemical properties between the integrin and its ligand.

2. **Conformational Changes:** Upon ligand binding, integrins undergo a conformational change, transitioning from a bent, inactive state to an extended, active state. This conformational change exposes the integrin's cytoplasmic domain, facilitating interactions with intracellular signaling molecules.

3. **Signal Transduction:** The binding of integrins to ECM proteins triggers a cascade of intracellular signaling events. These signals involve the recruitment of various adaptor proteins and kinases, which activate downstream signaling pathways that regulate cell adhesion, migration, differentiation, and survival.

4. **Cytoskeletal Linkage:** The cytoplasmic domain of integrins interacts with the cytoskeleton, primarily actin filaments. This interaction provides mechanical stability to the cell-matrix adhesion, enabling cells to withstand mechanical stress and maintain their structural integrity.

5. **Clustering and Focal Adhesions:** Integrin binding and signaling often lead to the clustering of integrins and associated proteins at specific sites on the cell membrane. These clusters, known as focal adhesions, serve as sites of force transmission between the cell and the ECM.

6. **Dynamic Regulation:** Cell-matrix adhesion is a dynamic process that is constantly regulated by various cellular factors. Integrins can undergo rapid turnover, allowing for the adjustment of cell adhesion in response to changes in the ECM or cellular environment.

These intricate molecular processes ensure the proper attachment and interaction of cells with their surrounding environment, contributing to tissue development, homeostasis, and wound healing.'
"

Proteins (1)

ProteinDefinitionTaxonomy
Integrin beta-1An integrin beta-1 that is encoded in the genome of human. [PRO:WCB, UniProtKB:P05556]Homo sapiens (human)

Compounds (17)

CompoundDefinitionClassesRoles
haloperidolhaloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.

Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
aromatic ketone;
hydroxypiperidine;
monochlorobenzenes;
organofluorine compound;
tertiary alcohol
antidyskinesia agent;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic;
serotonergic antagonist
1,3-ditolylguanidine1,3-ditolylguanidine: structure given in first source; a selective ligand for the sigma binding sites in the braintoluenes
tirofibantirofiban : A member of the class of piperidines that is L-tyrosine in which a hydrogen attached to the amino group is replaced by a butylsulfonyl group and in which the hydrogen attached to the phenolic hydroxy group is replaced by a 4-(piperidin-4-yl)butyl group.

Tirofiban: Tyrosine analog and PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX antagonist that inhibits PLATELET AGGREGATION and is used in the treatment of ACUTE CORONARY SYNDROME.
L-tyrosine derivative;
piperidines;
sulfonamide
anticoagulant;
fibrin modulating drug;
platelet glycoprotein-IIb/IIIa receptor antagonist
arginyl-glycyl-aspartic acidarginyl-glycyl-aspartic acid: amino acid sequence of basic unit of widespread cellular recognition systemoligopeptide
arginyl-glycyl-aspartyl-serinearginyl-glycyl-aspartyl-serine: corresponds to cell attachment site of fibronectin; located near carboxyl-terminal region of alpha-chain of fibrinogen; inhibits platelet aggregation & fibrinogen binding to activated platelets
glycyl-arginyl-glycyl-aspartyl-serineglycyl-arginyl-glycyl-aspartyl-serine: synthetic peptide from fibronectins; inhibits experimental metastasis of murine melanoma cells
d-arg-gly-asp-trparginyl-glycyl-aspartyl-tryptophan: a synthetic RGD-containing peptide
l 738167L 738167: structure in first source
cilengitideCilengitide: an alphaVbeta3 integrin antagonist that paralyzes cancer cellsoligopeptide
l 734217L 734217: fibrinogen receptor antagonist; structure given in first source
cyclopaminepiperidinesglioma-associated oncogene inhibitor
arginyl-glycyl-aspartyl-phenylalanine
cyclic(arg-gly-asp-d-phe-val)
mk-0429
mocetinostatmocetinostat : A benzamide obtained by formal condensation of the carboxy group of 4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}methyl)benzoic acid with one of the amino groups of benzene-1,2-diamine. It is an orally active and isotype-selective HDAC inhibitor which exhibits antitumour activity (IC50 = 0.15, 0.29, 1.66 and 0.59 muM for HDAC1, HDAC2, HDAC3 and HDAC11).

mocetinostat: undergoing phase II clinical trials for treatment of cancer
aminopyrimidine;
benzamides;
pyridines;
secondary amino compound;
secondary carboxamide;
substituted aniline
antineoplastic agent;
apoptosis inducer;
autophagy inducer;
cardioprotective agent;
EC 3.5.1.98 (histone deacetylase) inhibitor;
hepatotoxic agent
tr 14035N-(2,6-dichlorobenzoyl)-4-(2',6'-bismethoxyphenyl)phenylalanine: TR-14035 is the (L)-isomer; an antagonist of both alpha4beta1 and beta7 integrins; structure in first source
bio 1211BIO 1211: integrin alpha4beta1 inhibitor; structure in first source